iRhythm’s second quarter results were met with a strong positive market reaction, reflecting the company’s ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for the Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. CEO Quentin Blackford noted that the company’s operational discipline and successful integration of digital workflow tools were key factors behind the margin gains, stating that manufacturing automation and workflow optimization contributed to the uplift in gross margin. With new partnerships and expanding reach in both domestic and international markets, iRhythm’s momentum was broad-based this quarter.
Is now the time to buy IRTC? Find out in our full research report (it’s free for active Edge members).
iRhythm (IRTC) Q2 CY2026 Highlights:
- Revenue: $224.2 million vs analyst estimates of $219.2 million (20.1% year-on-year growth, 2.3% beat)
- Adjusted EPS: $0.58 vs analyst estimates of $0.04 (significant beat)
- Adjusted EBITDA: $43.3 million vs analyst estimates of $26.13 million (19.3% margin, 65.7% beat)
- The company slightly lifted its revenue guidance for the full year to $885 million at the midpoint from $880 million
- Operating Margin: -1.1%, up from -10% in the same quarter last year
- Market Capitalization: $4.13 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From iRhythm’s Q2 Earnings Call
-
Jon Young (Canaccord): asked about synergies from the VitalConnect acquisition, especially in the MCT business. CEO Quentin Blackford responded that a multi-product approach is needed to cover the full spectrum of physician and patient preferences in the MCT market, which the combined portfolio now addresses.
-
Anthony (Citi, for Joanne Wuensch): inquired about the sustainability of EBITDA margin gains and whether there was a tariff refund benefit. CFO Dan Wilson clarified that there was no tariff benefit and said future investment will balance growth with profitability.
-
Allen Gong (JPMorgan): questioned how VitalConnect positions iRhythm for new markets beyond MCT, such as remote patient monitoring and hospital-to-home. Blackford highlighted that the acquisition accelerates broader market entry and aligns with iRhythm’s multi-vital monitoring strategy.
-
Marie Thibault (BTIG): asked for an update on direct-to-patient marketing efforts. Blackford said the company is in early stages but intends to expand investment in these initiatives given the positive initial indicators.
-
Vijay Kumar (Evercore ISI): pressed on whether the acquisition would cannibalize iRhythm’s own MCT development and about anticipated share dilution. Blackford reaffirmed the need for multiple MCT solutions, while Wilson estimated share issuance would be less than 1.5% dilution.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will be watching (1) the integration and commercial rollout of VitalConnect’s platform, (2) the effectiveness of direct-to-patient and predictive analytics initiatives in driving new patient referrals, and (3) progress toward FDA clearance for Zio MCT and resolution of the outstanding FDA warning letter. Execution on international expansion and margin improvement from automation will also serve as important signposts of execution.
iRhythm currently trades at $125.36, down from $128.12 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
